SK bioscience announced on the 21st that it has created the position of Chief Operating Officer (COO), who oversees the company-wide value chain, and appointed Park Jin-sun, Head of Marketing & Business Development, as COO. The COO will serve as an “integrated control tower” connecting research and development, production, and overall business operations.

SK bioscience has also recruited external experts to strengthen its manufacturing and quality competitiveness. It appointed former Samsung Biologics Technical Support Center Head Lee Sang-yoon as Andong L House Plant Manager and Head of the Bio Research Division, and former Hanmi Pharmaceutical QA Group Head Lee Beom-han as Head of QE (Quality Excellence), overseeing quality.

The company stated that this organizational restructuring is intended to ensure that vaccine development, commercial production, and global collaboration operate organically within a single system. With the 21-valent pneumococcal vaccine, currently being co-developed with Sanofi, in global Phase 3 clinical trials and new vaccine projects entering full-scale development, more systematic operational management has become necessary, according to the company.

In particular, SK bioscience is significantly strengthening its research and process infrastructure, using its relocation to the Songdo Global R&PD Center as an opportunity. In line with this, SK bioscience plans to enhance organizational operating efficiency and more smoothly advance collaborations with global pharmaceutical companies.

Newly appointed COO Park Jin-sun has extensive experience ranging from research planning to business development and commercialization strategy, and will oversee the enhancement of competitiveness for in-house developed products and preparations for commercialization of new pipelines.

Bio Research Division Head Lee Sang-yoon, drawing on his experience in large-scale biopharmaceutical production and technology transfer, plans to promote manufacturing process design that considers global supply from the early stages of research. QE Head Lee Beom-han will focus on establishing a quality management system required for entry into overseas markets, leveraging his experience in responding to global regulatory authorities.

SK bioscience plans to complete an integrated management system that connects research, development, production, and quality into a single framework through this organizational restructuring and talent recruitment, and to further strengthen its competitiveness in the global vaccine and bio markets.

Popular News